Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 11/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2222165 | 1.00 | PDE4B (0.43) | PDE4BHTR6BCHECYP2C19KDM4E | |
| SCHEMBL26246793 | 0.99 | PDE4B (0.41) | PDE4BHTR6BCHECYP2C19KDM4E | |
| SCHEMBL14644516 | 0.91 | CDK7 (0.39) | HTR6CYP2C19DRD2HTR2ADRD3 | |
| SCHEMBL2278291 | 0.91 | CYP2C19 (0.39) | PDE4BHTR6BCHECYP2C19DRD2 | |
| SCHEMBL9989458 | 0.90 | L3MBTL1 (0.41) | PDE4BHTR6KDM4EGAAMAPT | |
| SCHEMBL10281621 | 0.90 | HTR6 (0.47) | HTR6CYP2C19DRD2HTR2ADRD3 | |
| SCHEMBL2273309 | 0.90 | ITK (0.38) | PDE4BHTR6BCHECYP2C19DRD2 | |
| SCHEMBL24491105 | 0.89 | CYP2C19 (0.37) | PDE4BHTR6BCHECYP2C19DRD2 | |
| SCHEMBL2291919 | 0.88 | HTR6 (0.35) | PDE4BHTR6BCHECYP2C19GAA | |
| SCHEMBL2274944 | 0.88 | HTR6 (0.43) | PDE4BHTR6BCHECYP2C19DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320212-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORP (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4620469-A2 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | Incyte Corporation (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4175719-B1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORP (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12187725-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-20240150354-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2024-05-09 | — | — | US | disclosed |
| US-11780840-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | INCYTE CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| EP-4175719-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | Incyte Corporation (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20220169649-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320212-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | PDE4B 3957/4885HTR6 4357/4885BCHE 4468/4885 |
| US-20240150354-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | PDE4B 3957/4885HTR6 4357/4885BCHE 4468/4885 |
| US-11780840-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | PDE4B 3957/4885HTR6 4357/4885BCHE 4468/4885 |
| US-12187725-B2 | Tricyclic urea compounds as JAK2 V617F inhibitors | JAK2, JAK1, JAK3 | PDE4B 3957/4885HTR6 4357/4885BCHE 4468/4885 |
| US-20220169649-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | PDE4B 3957/4885HTR6 4357/4885BCHE 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.